Loss of β-cell function is critical in the pathogenesis of T2D and may progress more rapidly in youth. We compared 3-hr OGTT model-derived measures of β-cell function in youth and adults with IGT or T2D in RISE treated for 12 mo with metformin (MET), or glargine followed by metformin (G/M) and 9 mo after treatment withdrawal. Model parameters included insulin sensitivity (OGIS), insulin secretion rate (ISR) at glucose 6.5 mM (ISR-6.5), total ISR (tISR), glucose sensitivity (GS: slope ISR vs. glucose concentration) and rate sensitivity (RS: ISR relative to glucose rate of change). Linear mixed models tested for differences by time (0-12 and 0-21 mo), age (youth vs. adults) and treatment (MET vs. G/M). Key observations included the following. Insulin sensitivity (OGIS) increased transiently in all but adults on G/M. In youth, insulin secretion (ISR-6.5 and tISR) and RS decreased relative to baseline, with GS also decreased in the G/M arm. In contrast, in adults there were no significant changes in modeled parameters at 21 mo. Insulin secretion and β-cell function parameters decreased more in youth vs. adults in the G/M arm. By treatment, GS decreased more in the G/M vs. MET arm in youth, but there were no differences in adults.

In conclusion, only youth exhibited worsening of features of β-cell function that can only be derived with mathematical modeling.


K. Utzschneider: Other Relationship; Self; Medtronic. M. Tripputi: None. M. Cree-Green: Advisory Panel; Self; Novo Nordisk Inc. T.S. Hannon: None. K.J. Nadeau: None. E. Barengolts: None. J.P. Palmer: None. K.J. Mather: Research Support; Self; Abbott, Merck & Co., Inc., Novo Nordisk Inc., Sanofi. S. Caprio: None. S. Edelstein: None. A. Mari: Consultant; Self; Lilly Diabetes. Research Support; Self; Boehringer Ingelheim International GmbH. T. Consortium: None.


American Diabetes Association (1-14-RISE-01); National Institute of Diabetes and Digestive and Kidney Diseases

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.